Literature DB >> 14707072

Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.

Sergei Kusmartsev1, Yulia Nefedova, Daniel Yoder, Dmitry I Gabrilovich.   

Abstract

Tumor growth is associated with the accumulation of immature myeloid cells (ImC), which in mice are characterized by the expression of Gr-1 and CD11b markers. These cells suppress Ag-specific CD8+ T cells via direct cell-cell contact. However, the mechanism of immunosuppressive activity of tumor-derived ImC remains unclear. In this study we analyzed the function of ImC isolated from tumor-free control and tumor-bearing mice. Only ImC isolated from tumor-bearing mice, not those from their control counterparts, were able to inhibit the Ag-specific response of CD8+ T cells. ImC obtained from tumor-bearing mice had significantly higher levels of reactive oxygen species (ROS) than ImC isolated from tumor-free animals. Accumulation of H2O2, but not superoxide or NO, was a major contributor to this increased pool of ROS. It appears that arginase activity played an important role in H2O2 accumulation in these cells. Inhibition of ROS in ImC completely abrogated the inhibitory effect of these cells on T cells, indicating that ImC generated in tumor-bearing hosts suppress the CD8+ T cell response via production of ROS. Interaction of ImC with Ag-specific T cells in the presence of specific Ags resulted in a significant increase in ROS production compared with control Ags. That increase was independent of IFN-gamma production by T cells, but was mediated by integrins CD11b, CD18, and CD29. Blocking of these integrins with specific Abs abrogated ROS production and ImC-mediated suppression of CD8+ T cell responses. This study demonstrates a new mechanism of Ag-specific T cell inhibition mediated by ROS produced by ImCs in cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14707072     DOI: 10.4049/jimmunol.172.2.989

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  337 in total

1.  Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells.

Authors:  Chun-Te Wu; Ching-Chuan Hsieh; Cheng-Chia Lin; Wen-Cheng Chen; Ji-Hong Hong; Miao-Fen Chen
Journal:  J Mol Med (Berl)       Date:  2012-06-03       Impact factor: 4.599

2.  Myeloid suppressor cells induced by retinal pigment epithelial cells inhibit autoreactive T-cell responses that lead to experimental autoimmune uveitis.

Authors:  Zhidan Tu; Yan Li; Dawn Smith; Catherine Doller; Sunao Sugita; Chi-Chao Chan; Shiguang Qian; John Fung; Rachel R Caspi; Lina Lu; Feng Lin
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-23       Impact factor: 4.799

Review 3.  Myeloid-derived suppressor cells in transplantation and cancer.

Authors:  Jordi C Ochando; Shu Hsia Chen
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

4.  Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice.

Authors:  Je-In Youn; Michelle Collazo; Irina N Shalova; Subhra K Biswas; Dmitry I Gabrilovich
Journal:  J Leukoc Biol       Date:  2011-09-27       Impact factor: 4.962

5.  Yeast-Derived Particulate β-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer.

Authors:  Sabrin H Albeituni; Chuanlin Ding; Min Liu; Xiaoling Hu; Fengling Luo; Goetz Kloecker; Michael Bousamra; Huang-ge Zhang; Jun Yan
Journal:  J Immunol       Date:  2016-01-25       Impact factor: 5.422

6.  HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity.

Authors:  Ankita Garg; Stephen A Spector
Journal:  J Infect Dis       Date:  2013-09-01       Impact factor: 5.226

Review 7.  Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB.

Authors:  Thorsten Hagemann; Subhra K Biswas; Toby Lawrence; Antonio Sica; Claire E Lewis
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

8.  Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.

Authors:  Carmela De Santo; Paolo Serafini; Ilaria Marigo; Luigi Dolcetti; Manlio Bolla; Piero Del Soldato; Cecilia Melani; Cristiana Guiducci; Mario P Colombo; Manuela Iezzi; Piero Musiani; Paola Zanovello; Vincenzo Bronte
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

Review 9.  Altered macrophage differentiation and immune dysfunction in tumor development.

Authors:  Antonio Sica; Vincenzo Bronte
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 10.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.